Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Fusion Antibodies (FAB) Share Price

Price 6.65p on 15-04-2025 at 05:00:03
Change 0.00p 0%
Buy 0.00p
Sell 0.00p
Buy / Sell FAB Shares
Last Trade: Buy 7.00 at 6.80p
Day's Volume: 0
Last Close: 6.65p
Open: 0.00p
ISIN: GB00BDQZGK16
Day's Range 0.00p - 0.00p
52wk Range: 2.90p - 10.50p
Market Capitalisation: £7m
VWAP: 0.00p
Shares in Issue: 105m

Fusion Antibodies (FAB) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 7 6.80p Ordinary
16:29:34 - 14-Apr-25
Buy* 7 6.80p Ordinary
16:29:14 - 14-Apr-25
Buy* 7 6.80p Ordinary
16:25:55 - 14-Apr-25
Sell* 36,190 6.406p Ordinary
16:23:08 - 14-Apr-25
Buy* 7 6.802p Ordinary
16:23:03 - 14-Apr-25
Unknown* 119,605 6.452p Ordinary
16:22:19 - 14-Apr-25
Unknown* 100,000 6.525p Ordinary
16:13:12 - 14-Apr-25
Sell* 40,000 6.55p Ordinary
16:10:45 - 14-Apr-25
Buy* 1,954 6.8865p Ordinary
15:54:56 - 14-Apr-25
Buy* 8 6.98p Ordinary
15:36:43 - 14-Apr-25
See more Fusion Antibodies trades

Fusion Antibodies (FAB) Share Price History

Time period:
to
Date Open High Low Close Volume
14th Apr 2025 (Mon) 6.55 6.75 6.55 6.65 1,296,206
11th Apr 2025 (Fri) 6.60 7.00 6.55 6.55 1,061,439
10th Apr 2025 (Thu) 6.60 6.60 6.60 6.60 270,483
9th Apr 2025 (Wed) 6.55 6.55 6.25 6.25 543,916
8th Apr 2025 (Tue) 6.55 6.60 6.55 6.60 250,220
7th Apr 2025 (Mon) 6.25 6.60 6.05 6.55 1,348,977
4th Apr 2025 (Fri) 6.25 6.30 6.20 6.20 593,934
3rd Apr 2025 (Thu) 6.20 6.25 6.15 6.25 587,532
2nd Apr 2025 (Wed) 6.40 6.40 6.25 6.25 450,729
1st Apr 2025 (Tue) 6.15 6.30 6.30 6.40 1,856,384
31st Mar 2025 (Mon) 6.50 6.50 6.15 6.15 1,224,537
28th Mar 2025 (Fri) 6.50 6.50 6.50 6.50 105,300
27th Mar 2025 (Thu) 6.50 6.50 6.50 6.50 571,380
26th Mar 2025 (Wed) 6.55 6.55 6.50 6.50 369,974
25th Mar 2025 (Tue) 6.25 6.70 6.25 6.55 2,004,127
24th Mar 2025 (Mon) 6.60 6.60 5.95 6.25 2,043,167
21st Mar 2025 (Fri) 6.60 6.60 6.60 6.60 44,753
20th Mar 2025 (Thu) 6.70 6.70 6.60 6.60 452,761
19th Mar 2025 (Wed) 6.40 6.90 6.90 6.90 1,692,367
18th Mar 2025 (Tue) 6.40 6.75 6.40 6.40 3,512,045
17th Mar 2025 (Mon) 6.75 6.75 6.30 6.75 837,877
See more Fusion Antibodies price history

Fusion Antibodies (FAB) Regulatory News

Date Source Headline
11th Apr 2025 10:40 am RNS Holding(s) in Company
10th Apr 2025 12:47 pm RNS Holding(s) in Company
7th Apr 2025 12:35 pm RNS Result of General Meeting
31st Mar 2025 5:00 pm RNS Total Voting Rights
24th Mar 2025 4:38 pm RNS Holding(s) in Company
18th Mar 2025 7:00 am RNS Placing to raise approximately £1.17 million
27th Feb 2025 7:00 am RNS Contract win
31st Jan 2025 7:00 am RNS OptiMAL R&D Update
4th Dec 2024 11:31 am RNS Approval of Grant Funding Application
19th Nov 2024 7:00 am RNS Half-year Report
See more Fusion Antibodies regulatory news

Fusion Antibodies (FAB) Share News

Fusion Antibodies receives approval of grant funding application

4th Dec 2024 12:18

(Alliance News) - Fusion Antibodies PLC on Wednesday announced the approval of a grant funding application to The Northern Ireland Precision Biomarkers & Therapeutics consortium, of which it is a member. Read More

Fusion Antibodies interim loss narrows as revenue more than doubles

19th Nov 2024 13:10

(Alliance News) - Fusion Antibodies PLC on Tuesday said its loss narrowed in the first half of its current financial year, as revenue more than doubled. Read More

IN BRIEF: Fusion Antibodies expects interim revenue to double

8th Oct 2024 13:58

Fusion Antibodies PLC - Belfast-based contract researcher that provides discovery, design and optimisation services for therapeutic antibodies to the healthcare market - Expects revenue of around GBP1.2 million for the six months to September 30, more than doubling from GBP541,000 at the same time last year. Its gross margin is expected to be 29%, compared to negative 16% the year prior. Fusion Antibodies expands its collaboration agreement with the National Cancer Institute in the six-month period to include the company's humanisation of the NCI's existing camelid nanobodies, and secures a new contract for an antibody based therapeutic with an unnamed US-based biotechnology company. It is also contracted to develop a bespoke OptiPhage library for an unnamed client. The company remains on track with its strategic goals. Read More

UK shareholder meetings calendar - next 7 days

1st Oct 2024 15:33

Read More

Fusion Antibodies expands agreement with National Cancer Institute

28th Aug 2024 13:52

(Alliance News) - Fusion Antibodies PLC on Wednesday said it is expanding its collaboration agreement with the National Cancer Institute. Read More

See more Fusion Antibodies news
FTSE 100 Latest
Value8,134.34
Change0.00

Login to your account

Forgot Password?

Not Registered